journal article·2018-01-17

Light-Activatable Theranostic Agents for Image-Monitored Controlled Drug Delivery

Zhe Zhang, Madison Taylor, Courtney Collins, Sara Haworth, ZhanQuan Shi, Zheng Yuan, Xingyu He, Zishu Cao, Yoonjee C. Park

Publisher page

Abstract

A novel drug delivery vehicle using nanodroplets activated by light irradiation for drug release in a controlled manner has been developed. The drug encapsulated in the nanodroplets was released upon phase transition from a liquid droplet to microbubbles (vaporization) by plasmonic photothermal heat from gold nanorods adsorbed on the surface of the nanodroplets. The nanodroplets were stable against aggregation and dissolution at 4 °C over 3 months to date. The phase transition was quantitatively analyzed by ultrasound imaging to examine the amount of drug release noninvasively. In vitro studies showed that cell death occurred only when light irradiation was performed on the drug-encapsulated nanodroplets. Ex vivo studies demonstrated a potential application of the nanodroplets for treating posterior eye diseases. Thus, it has been demonstrated that our gold-nanorod-coated light-activatable nanodroplets can be a candidate for a controlled release and a dosage-monitored drug delivery system.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Photoacoustic and Ultrasonic Imaging · Gold and Silver Nanoparticles Synthesis and Applications · Ultrasound and Hyperthermia Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical, Chemical & Environmental Engineering and ‡College of Pharmacy, University of Cincinnati, Cincinnati 45221, Ohio, United States

Funding

University of Cincinnati

References (35)

Show source-provided references
1. 10.1016/j.addr.2012.01.01610.1016/j.addr.2012.01.016 ↗
2. 10.1098/rsif.2010.022310.1098/rsif.2010.0223 ↗
3. 10.1155/2013/40436110.1155/2013/404361 ↗
4. 10.1007/s11095-010-0277-510.1007/s11095-010-0277-5 ↗
5. 10.1016/j.ultrasmedbio.2010.04.01910.1016/j.ultrasmedbio.2010.04.019 ↗
6. 10.1021/acs.nanolett.5b0344010.1021/acs.nanolett.5b03440 ↗
7. 10.1016/j.jss.2014.07.03610.1016/j.jss.2014.07.036 ↗
8. 10.1364/BOE.2.00143210.1364/BOE.2.001432 ↗
9. 10.1364/BOE.5.00441710.1364/BOE.5.004417 ↗
10. 10.1002/adfm.20140263110.1002/adfm.201402631 ↗
11. 10.2147/NDT.S7818210.2147/NDT.S78182 ↗
12. 10.1021/jp991764810.1021/jp9917648 ↗
13. 10.1021/la204510h10.1021/la204510h ↗
14. 10.1021/nn901144d10.1021/nn901144d ↗
15. 10.1016/S1748-0132(07)70016-610.1016/S1748-0132(07)70016-6 ↗
16. 10.1021/nl050693n10.1021/nl050693n ↗
17. 10.1103/PhysRevB.84.03541510.1103/PhysRevB.84.035415 ↗
18. 10.1016/j.jconrel.2013.07.00310.1016/j.jconrel.2013.07.003 ↗
19. Peng, Z.; Porter, T.InAn in Vitro Study of Phase Shift Nano-Emulsion in Focused Ultrasound Surgery: Its Potential for Enhancing Ultrasound-Mediated Hyperthermia, IEEE 35th Annual Northeast Bioengineering Conference, April 3–5, 2009; pp1–2.10.1109/NEBC.2009.4967663 ↗
20. 10.1001/jamaophthalmol.2013.766610.1001/jamaophthalmol.2013.7666 ↗
21. 10.1001/archophthalmol.2012.198310.1001/archophthalmol.2012.1983 ↗
22. 10.1039/C0CP00553C10.1039/C0CP00553C ↗
23. 10.1021/nn100022210.1021/nn1000222 ↗
24. Smith S. B. · Invest. Ophthalmol. Visual Sci. · 1999 · 40 · 840
25. 10.1167/iovs.09-483310.1167/iovs.09-4833 ↗
26. Gibney, M.NuvOx Pharma Receives Exclusive License from University of ArkansasFiercePharma 2014.
27. 10.1021/la501536210.1021/la5015362 ↗
28. 10.1021/la201370510.1021/la2013705 ↗
29. 10.1016/j.jconrel.2011.01.02210.1016/j.jconrel.2011.01.022 ↗
30. 10.1039/c1lc20615j10.1039/c1lc20615j ↗
31. 10.1016/S0301-5629(00)00262-310.1016/S0301-5629(00)00262-3 ↗
32. 10.1016/j.ultrasmedbio.2010.07.00110.1016/j.ultrasmedbio.2010.07.001 ↗
33. 10.1016/j.ultrasmedbio.2010.06.02010.1016/j.ultrasmedbio.2010.06.020 ↗
34. 10.1016/j.jconrel.2015.02.02810.1016/j.jconrel.2015.02.028 ↗
35. 10.1016/S0161-6420(86)33629-710.1016/S0161-6420(86)33629-7 ↗